ClinicalTrials.gov record
Completed Phase 1 Interventional

A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

ClinicalTrials.gov ID: NCT01649336

Public ClinicalTrials.gov record NCT01649336. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 6:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Study identification

NCT ID
NCT01649336
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Array Biopharma, now a wholly owned subsidiary of Pfizer
Industry
Enrollment
36 participants

Conditions and interventions

Interventions

  • MEK162, MEK inhibitor; oral Drug
  • Paclitaxel, mitotic inhibitor; intravenous Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2012
Primary completion
Feb 29, 2016
Completion
Feb 29, 2016
Last update posted
Sep 13, 2020

2012 – 2016

United States locations

U.S. sites
4
U.S. states
4
U.S. cities
4
Facility City State ZIP Site status
Pfizer Investigational Site Scottsdale Arizona
Pfizer Investigational Site Lafayette Indiana
Pfizer Investigational Site New York New York
Pfizer Investigational Site Oklahoma City Oklahoma

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01649336, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 13, 2020 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01649336 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →